Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant ...

Sanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug ...

Boehringer Ingelheim subsidiary NBE Therapeutics has opened its new antibody-drug conjugates (ADC) R&D facility in Basel, ...

Roche outlined how digital health technologies (DHTs) provide more sensitive measures of disease progression in early ...

Astellas Pharma has entered a strategic partnership with the JFCR to expedite research in translational and clinical oncology ...

If preclinical findings were translated into the clinic, they could shorten the CAR-T generation lead time from two weeks to ...

Late-stage pipeline products anticipated to reach the uveitis market during the forecast period will introduce new mechanisms ...

UK Government drug sale clawbacks must be eased for pharma innovation to meet its ten-year plan, say industry representatives ...

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast ...

According to a factsheet published by the Trump administration, pharmaceuticals are exempted from the tariffs – for now.

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US government to add to vaccine ...

Atsena Therapeutics has completed an oversubscribed Series C financing round, raising $150m to support the advancement of ...